Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies

References

• Rosenthal MC, Saunders RH, Schwartz LI, Zannos L, Perez Santiago E, Dameshek W. The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma. Blood 1951; 6:804 - 23; PMID: 14869344
   PubMed Web of Science ®Google Scholar
• Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003; 31:271 - 82; http://dx.doi.org/10.1016/S0301-472X(03)00023-7; PMID: 12691914
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118:5752 - 8, quiz 5982; http://dx.doi.org/10.1182/blood-2011-05-355081; PMID: 21849487
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11:164 - 79; http://dx.doi.org/10.1016/j.drup.2008.08.002; PMID: 18818117
   PubMed Web of Science ®Google Scholar
• Schlossmacher G, Stevens A, White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 2011; 211:17 - 25; http://dx.doi.org/10.1530/JOE-11-0135; PMID: 21602312
   PubMed Web of Science ®Google Scholar
• Chebotaev D, Yemelyanov A, Budunova I. The mechanisms of tumor suppressor effect of glucocorticoid receptor in skin. Mol Carcinog 2007; 46:732 - 40; http://dx.doi.org/10.1002/mc.20349; PMID: 17538956
   PubMed Web of Science ®Google Scholar
• Adcock IM. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 2001; 14:211 - 9; http://dx.doi.org/10.1006/pupt.2001.0283; PMID: 11448148
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163:29 - 43; http://dx.doi.org/10.1111/j.1476-5381.2010.01199.x; PMID: 21198556
   PubMed Web of Science ®Google Scholar
• Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 2004; 1:239 - 46; http://dx.doi.org/10.1513/pats.200402-005MS; PMID: 16113441
   PubMedGoogle Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003; 24:488 - 522; http://dx.doi.org/10.1210/er.2002-0006; PMID: 12920152
   PubMed Web of Science ®Google Scholar
• Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007; 26:1885 - 96; http://dx.doi.org/10.1038/sj.onc.1209991; PMID: 17016446
   PubMed Web of Science ®Google Scholar
• Chebotaev D, Yemelyanov A, Zhu L, Lavker RM, Budunova I. The tumor suppressor effect of the glucocorticoid receptor in skin is mediated via its effect on follicular epithelial stem cells. Oncogene 2007; 26:3060 - 8; http://dx.doi.org/10.1038/sj.onc.1210108; PMID: 17146443
   PubMed Web of Science ®Google Scholar
• Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004; 101:227 - 32; http://dx.doi.org/10.1073/pnas.0300372101; PMID: 14694204
   PubMed Web of Science ®Google Scholar
• Schäcke H, Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009; 158:1088 - 103; http://dx.doi.org/10.1111/j.1476-5381.2009.00238.x; PMID: 19422381
   PubMed Web of Science ®Google Scholar
• Hu X, Du S, Tunca C, Braden T, Long KR, Lee J, et al. The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation. Endocrinology 2011; 152:3123 - 34; http://dx.doi.org/10.1210/en.2010-1447; PMID: 21558312
   PubMed Web of Science ®Google Scholar
• Swart P, Swart AC, Louw A, van der Merwe KJ. Biological activities of the shrub Salsola tuberculatiformis Botsch.: contraceptive or stress alleviator?. Bioessays 2003; 25:612 - 9; http://dx.doi.org/10.1002/bies.10285; PMID: 12766951
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005; 102:15827 - 32; http://dx.doi.org/10.1073/pnas.0505554102; PMID: 16243974
   PubMed Web of Science ®Google Scholar
• Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr., Budunova I. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res 2008; 68:4763 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-07-6104; PMID: 18559523
   PubMed Web of Science ®Google Scholar
• Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008; 180:2608 - 15; PMID: 18250472
   PubMed Web of Science ®Google Scholar
• Robertson S, Allie-Reid F, Vanden Berghe W, Visser K, Binder A, Africander D, et al. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. J Biol Chem 2010; 285:8061 - 75; http://dx.doi.org/10.1074/jbc.M109.087866; PMID: 20037160
   PubMed Web of Science ®Google Scholar
• van Loo G, Sze M, Bougarne N, Praet J, Mc Guire C, Ullrich A, et al. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol Endocrinol 2010; 24:310 - 22; http://dx.doi.org/10.1210/me.2009-0236; PMID: 19965930
   PubMed Web of Science ®Google Scholar
• Wüst S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, et al. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One 2009; 4:e8202; http://dx.doi.org/10.1371/journal.pone.0008202; PMID: 19997594
   PubMed Web of Science ®Google Scholar
• Rauner M, Goettsch C, Stein N, Thiele S, Bornhaeuser M, De Bosscher K, et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology 2011; 152:103 - 12; http://dx.doi.org/10.1210/en.2010-0456; PMID: 21084452
   PubMed Web of Science ®Google Scholar
• Geley S, Hartmann BL, Hala M, Strasser-Wozak EM, Kapelari K, Kofler R. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res 1996; 56:5033 - 8; PMID: 8895760
   PubMed Web of Science ®Google Scholar
• Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle 2012; 11:395 - 406; http://dx.doi.org/10.4161/cc.11.2.18945; PMID: 22223138
   PubMed Web of Science ®Google Scholar
• Wallace AD, Cao Y, Chandramouleeswaran S, Cidlowski JA. Lysine 419 targets human glucocorticoid receptor for proteasomal degradation. Steroids 2010; 75:1016 - 23; http://dx.doi.org/10.1016/j.steroids.2010.06.015; PMID: 20619282
   PubMed Web of Science ®Google Scholar
• Kofler R, Schmidt S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003; 178:19 - 27; http://dx.doi.org/10.1677/joe.0.1780019; PMID: 12844332
   PubMed Web of Science ®Google Scholar
• Gross KL, Oakley RH, Scoltock AB, Jewell CM, Cidlowski JA. Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance. Mol Endocrinol 2011; 25:1087 - 99; http://dx.doi.org/10.1210/me.2010-0051; PMID: 21527497
   PubMed Web of Science ®Google Scholar
• Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300:7 - 16; http://dx.doi.org/10.1016/j.mce.2008.10.001; PMID: 19000736
   PubMed Web of Science ®Google Scholar
• Ruiz M, Lind U, Gåfvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, et al. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf) 2001; 55:363 - 71; http://dx.doi.org/10.1046/j.1365-2265.2001.01323.x; PMID: 11589680
   PubMed Web of Science ®Google Scholar
• Beesley AH, Weller RE, Senanayake S, Welch M, Kees UR. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines. Leuk Res 2009; 33:321 - 5; http://dx.doi.org/10.1016/j.leukres.2008.08.007; PMID: 18789525
   PubMed Web of Science ®Google Scholar
• Irving JA, Minto L, Bailey S, Hall AG. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res 2005; 65:9712 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-1227; PMID: 16266991
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006; 25:6868 - 86; http://dx.doi.org/10.1038/sj.onc.1209935; PMID: 17072333
   PubMed Web of Science ®Google Scholar
• van Rossum EF, van den Akker EL. Glucocorticoid resistance. Endocr Dev 2011; 20:127 - 36; PMID: 21164266
   PubMedGoogle Scholar
• Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001; 276:42714 - 21; http://dx.doi.org/10.1074/jbc.M106033200; PMID: 11555652
   PubMed Web of Science ®Google Scholar
• Wiederrecht G, Hung S, Chan HK, Marcy A, Martin M, Calaycay J, et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. J Biol Chem 1992; 267:21753 - 60; PMID: 1383226
   PubMed Web of Science ®Google Scholar
• Stechschulte LA, Sanchez ER. FKBP51-a selective modulator of glucocorticoid and androgen sensitivity. Curr Opin Pharmacol 2011; 11:332 - 7; http://dx.doi.org/10.1016/j.coph.2011.04.012; PMID: 21565552
   PubMed Web of Science ®Google Scholar
• Chun E, Lee HS, Bang BR, Kim TW, Lee SH, Kim JH, et al. Dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells could play a role in predicting the response of asthmatics to treatment with corticosteroids. J Clin Immunol 2011; 31:122 - 7; http://dx.doi.org/10.1007/s10875-010-9463-9; PMID: 20853021
   PubMed Web of Science ®Google Scholar
• Schäcke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007; 275:109 - 17; http://dx.doi.org/10.1016/j.mce.2007.05.014; PMID: 17630119
   PubMed Web of Science ®Google Scholar
• Tanner T, Claessens F, Haelens A. The hinge region of the androgen receptor plays a role in proteasome-mediated transcriptional activation. Ann N Y Acad Sci 2004; 1030:587 - 92; http://dx.doi.org/10.1196/annals.1329.068; PMID: 15659841
   PubMed Web of Science ®Google Scholar
• López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, et al. LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 2008; 149:2080 - 9; http://dx.doi.org/10.1210/en.2007-1353; PMID: 18218700
   PubMed Web of Science ®Google Scholar
• Gossye V, Elewaut D, Bougarne N, Bracke D, Van Calenbergh S, Haegeman G, et al. Differential mechanism of NF-kappaB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:3241 - 50; http://dx.doi.org/10.1002/art.24963; PMID: 19877072
   PubMed Web of Science ®Google Scholar
• U M, Shen L, Oshida T, Miyauchi J, Yamada M, Miyashita T, U M. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 2004; 18:1850 - 6; http://dx.doi.org/10.1038/sj.leu.2403516; PMID: 15385927
   PubMed Web of Science ®Google Scholar
• Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer 2011; 104:19 - 23; http://dx.doi.org/10.1038/sj.bjc.6606014; PMID: 21119664
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259 - 66; http://dx.doi.org/10.1016/j.ccr.2009.07.016; PMID: 19732725
   PubMed Web of Science ®Google Scholar
• Kinyamu HK, Jefferson WN, Archer TK. Intersection of nuclear receptors and the proteasome on the epigenetic landscape. Environ Mol Mutagen 2008; 49:83 - 95; http://dx.doi.org/10.1002/em.20360; PMID: 18095329
   PubMed Web of Science ®Google Scholar
• Wang X, DeFranco DB. Alternative effects of the ubiquitin-proteasome pathway on glucocorticoid receptor down-regulation and transactivation are mediated by CHIP, an E3 ligase. Mol Endocrinol 2005; 19:1474 - 82; http://dx.doi.org/10.1210/me.2004-0383; PMID: 15761032
   PubMed Web of Science ®Google Scholar
• Adler J, Reuven N, Kahana C, Shaul Y. c-Fos proteasomal degradation is activated by a default mechanism, and its regulation by NAD(P)H:quinone oxidoreductase 1 determines c-Fos serum response kinetics. Mol Cell Biol 2010; 30:3767 - 78; http://dx.doi.org/10.1128/MCB.00899-09; PMID: 20498278
   PubMed Web of Science ®Google Scholar
• Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2:209 - 21; PMID: 21444945
   PubMed Web of Science ®Google Scholar
• Grant S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget 2011; 2:284 - 6; PMID: 21525531
   PubMed Web of Science ®Google Scholar
• Fulda S. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. Oncotarget 2011; 2:418 - 21; PMID: 21789791
   PubMed Web of Science ®Google Scholar
• Pandit B, Gartel AL. FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy. Cell Cycle 2011; 10:3269 - 73; http://dx.doi.org/10.4161/cc.10.19.17735; PMID: 21941087
   PubMed Web of Science ®Google Scholar
• Bretschneider H, Biemann K, Sachsenmaier W, Phenylalkanolamines V. Chlorophenethylamine derivatives and their conversion into halogen-free compounds. Monatsh Chem 1948; 78:82 - 116; http://dx.doi.org/10.1007/BF00942491
   Web of Science ®Google Scholar
• Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72:9873 - 80; PMID: 9811723
   PubMed Web of Science ®Google Scholar